A Study to Investigate Safety With Risankizumab in Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit of Study M16-002 (NCT02719171)

* Participants who have completed all doses of study drug and Week 24 visit of the lead-in study. * Women of childbearing potential who are sexually active, must agree to use at least one accepted method of contraception throughout the study, including 20 weeks after last dose of study drug is given. * Women of childbearing potential must have a negative urine pregnancy test at Baseline (Week 0/V1). * Participants must voluntarily sign and date an informed consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any study specific procedures. * Participant is judged to be in good health as determined by the Investigator.

* Female participant who is pregnant, breastfeeding or is considering becoming pregnant during study participation, including 20 weeks after the last dose of study drug is given. * Premature discontinuation of the study drug in the lead-in study for any reason. * Use of a biologic treatment other than risankizumab since first dose of study drug in the lead-in study. * Time elapsed is \> 8 weeks since the Week 24 visit in the lead-in study. * Active systemic infections during the last 2 weeks (exception: common cold) prior to the first dose, as assessed by the investigator.